Beam Therapeutics, Inc. (BEAM)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Beam Therapeutics, Inc. (BEAM)
Go deeper and ask any question about BEAM
Company Performance
Current Price
as of Sep 13, 2024$26.30
P/E Ratio
N/A
Market Cap
$2.17B
Description
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Metrics
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerBEAM
- Price$26.3+7.79%
Trading Information
- Market Cap$2.17B
- Float86.87%
- Average Daily Volume (1m)656,201
- Average Daily Volume (3m)1,123,359
- EPS-$1.76
Company
- Revenue$352.57M
- Rev Growth (1yr)-41.48%
- Net Income-$91.05M
- Gross Margin52.63%
- EBITDA Margin-843.69%
- EBITDA-$99.32M
- EV$1.09B
- EV/Revenue3.08
- P/EN/A
- P/S6.14
Documents
SEC Filings
Factset Street Account
Factset